JAK1 and rheumatoid arthritis: JAK inhibitors proven to be potent anti-inflammatory drugs include tofacitinib (inhibiting JAK1/2/3), baricitinib (inhibiting JAK1/2), and upadacitinib (selectively inhibiting JAK1), all of which have received FDA approval for treating rheumatoid arthritis.